Julia Gaebler, Lucy Therapeutics
US biotech Lucy Therapeutics has announced the appointment of Julia Gaebler as Chief Business Officer. Gaebler will direct fundraising, growth and partnership activities for its proprietary preclinical compounds in Parkinson’s disease, Rett syndrome and other diseases of mitochondrial dysfunction.
Martin Čadek, Sanitized
Swiss-based Sanitized, a producer of antimicrobial hygiene function and material protection for textiles and polymers, has appointed Martin Čadek as its new CTO. He will oversee global technological activities for the specialist antimicrobial hygiene brand and lead the company’s Competence Centre for Technology Innovation.
Jérôme Marzinski, OxSonics Therapeutics
Jérôme Marzinski has been appointed CE of OxSonics Therapeutics, an Oxford, UK-based company developing cancer treatment through SonoTran, its ultrasound-based drug delivery platform.
Richard Bungay, Imophoron
Richard Bungay has joined Imophoron as its new CEO. The Bristol, UK-based start-up biopharma is developing novel, next-generation nanoparticle vaccine products using its ADDomer platform.
David Jiménez, Moderna
At US pharma and biotech Moderna, David Jiménez has been named as General Manager, US. He will be responsible for commercial efforts in the US, reporting to Arpa Garay, Moderna’s Chief Commercial Officer.
Daniela Vlad, OMV Aktiengesellschaft
The Supervisory Board of Austrian multinational integrated oil, gas and petrochemical company OMV Aktiengesellschaft has appointed Daniela Vlad as the new Executive Board Member responsible for Chemicals & Materials. Vlad will take up the post with effect from 1 February 2023, moving on from paints and coatings company AkzoNobel. Alfred Stern, Chairman of the Executive Board and CEO of OMV, will continue to be responsible for the Chemicals & Materials business until she takes up her Board seat.
Dipal Patel, Valneva
French biotech Valneva has appointed Dipal Patel as Chief Commercial Officer and management board member to help it prepare for the potential market launch in 2023 of its vaccine against chikungunya virus, a mosquito-borne virus that can lead to fever and joint pain. There is currently no vaccine to prevent, or medicine to treat chikungunya. Patel was formerly the international commercial leader for shingles vaccine Shingrix at UK pharma GSK.
Ryan Kruger, Anagenex
Ryan Kruger has moved on from his role as GSK’s VP, Head of the Cancer Epigenetics Research Unit, Oncology R&D to Anagenex, where he will be CSO. He will be leading Anagenex’s scientific and drug discovery strategy from target selection to compound development.
Matthew Frankel, Chemomab Therapeutics
Israeli clinical-stage biotech Chemomab Therapeutics, a company focused on the discovery and development of therapeutics for fibrotic and inflammatory diseases, has named Matthew Frankel as its new Chief Medical Officer and Vice President of Drug Development.
Bo Jesper Hansen, Swedish Orphan Biovitrum
Biopharma Swedish Orphan Biovitrum (Sobi) has announced the nomination of Bo Jesper Hansen as chairman of the board of directors to replace Håkan Björklund, who is stepping down from the position. Hansen is a co-founder of Sobi and currently deputy board chairman.
Hozefa Amijee, Ubiquigent
UK biotech Ubiquigent has appointed Hozefa Amijee as head of business development to help strengthen the company’s commercial partnerships and further improve its contract research services. Ubiquigent is developing modulators of deubiquitinase enzymes as new therapeutics.
Robert Davis, Merck & Co.
Robert Davis, Chief Executive of US pharma Merck & Co, has been appointed Chairman of the Board of Directors. He succeeds Kenneth Frazier, former CEO and Chair, who is retiring after a career at Merck that began in 1992. Davis joined Merck as CFO in 2014 and became president in April 2021. He was named CEO and a member of the board in July of that year.
Raymond Pratt, Savara
US company Savara, a clinical-stage biopharma focused on rare respiratory diseases, has appointed Raymond Pratt its CMO following the September resignation of Badrul Chowdhury.
Peter Graham & Kristen Harrington-Smith, ADC Therapeutics
Swiss biotech ADC Therapeutics has added two executives to its leadership team as it progresses its antibody-drug conjugate (ADC) drugs for cancer. Peter Graham becomes Chief Legal Officer and Kristen Harrington-Smith has been appointed Chief Commercial Officer.
Richard Ward, The Airedale Group
The Airedale Group, a UK company that operates in industrial/general chemicals, metal surface treatment, food and beverage ingredients and chemical packing and fulfilment services, has appointed Richard Ward as group business director. Ward joins the company from German chemical distribution company Brenntag, where he was President for the UK & Ireland Essentials business and a board member for 13 years.
Richard Ward, The Airedale Group
The Airedale Group, a UK company that operates in industrial/general chemicals, metal surface treatment, food and beverage ingredients and chemical packing and fulfilment services, has appointed Richard Ward as group business director. Ward joins the company from German chemical distribution company Brenntag, where he was President for the UK & Ireland Essentials business and a board member for 13 years.
David DiGiusto, Garuda Therapeutics
Garuda Therapeutics, a US company creating ‘off-the-shelf’, durable blood stem cell therapies, has named David DiGiusto as its new CTO. DiGiusto previously served as CTO and SVP Stem Cells and Regenerative Medicine at US manufacturing and technology company National Resilience, a biomanufacturer focused on broadening access to complex medicines.
Richard Francis, Teva Pharmaceutical Industries
Israeli multinational pharma Teva Pharmaceutical Industries has announced that the company’s Board of Directors has appointed Richard Francis as President and CEO, effective 1 January 2023. Kåre Schultz, Teva’s current CEO will retire on 31 December 2022.
Bart De Strooper, UK Dementia Research Institute
After six years as director of the UK Dementia Research Institute (UK DRI), Bart De Strooper has announced plans to step down so he can focus on his research at the University College London (UCL) Queen Square Institute of Neurology. Based at UCL, the UK DRI is the single biggest investment the UK has ever made in dementia, primarily supported by the Medical Research Council and charity funders Alzheimer’s Research UK and Alzheimer’s Society. De Strooper will remain in post until the UK DRI finds a successor.
Visit Blog.ashx?h=300&w=290&hash=2388D10BD6C879F15F7B5C61C48976D4)
